Table 2

Secondary prevention at inclusion according to current recommendations

CAD patientsAll CAD
(n=6313)		CAD alone
(n=4303)		CAD+AF
(n=700)		HF+CAD
(n=728)		HF+CAD+AF
(n=582)
An antithrombotic* drug for all patients with CAD99.099.4 reference98.3
p=0.017		98.6
p=0.044		97.6
p=0.001
A statin for all patients with CAD91.092.3 reference85.6
p<0.0001		90.4
p=0.106		84.2
p<0.0001
An ACE-I or ARB for patients with CAD if presence of other conditions (eg, HF, hypertension or diabetes)87.588.0 reference84.2
p=0.346		90.8
p=0.011		84.0
p=0.473
Patients with AFAll AF
(n=4973)		AF alone
(n=2604)		CAD+AF
(n=700)		HF+AF
(n=1087)		HF+CAD+AF
(n=582)
An oral anticoagulant for AF patients with a CHA2DS2-VASc score ≥2 for men and ≥3 for women81.780.9 reference71.9
p<0.0001		87.8
p<0.0001		85.1
p=0.015
Patients with HFAll HF
(n=2910)		HF alone
(n=513)		HF+CAD
(n=728)		HF+AF
(n=1087)		HF+CAD+AF
(n=582)
An ACE-I or ARB for HF patients with LVEF <40%90.993.2 reference93.0
p=0.939		87.3
p=0.091		89.2
p=0.210
A beta-blocker for HF patients with LVEF <40%91.089.8 reference93.0
p=0.261		93.0
p=0.314		87.6
p=0.527
An MRA for HF patients with LVEF ≤35%43.044.5 reference47.8
p=0.558		36.8
p=0.199		40.5
p=0.489
An ICD for HF patients with LVEF ≤35%39.931.3 reference48.2
p=0.002		30.2
p=0.846		43.6
p=0.033

  • Data are presented as the percentage of patients actually treated according to the recommendation out of the total number of patients relevant to this recommendation. Age-adjusted and sex-adjusted p values were obtained by logistic regression with the single-disease groups (CAD alone, AF alone and HF alone) as the references.

  • *Antiplatelet drug and/or oral anticoagulant.

  • ACE-I, ACE inhibitor; AF, atrial fibrillation; ARB, angiotensin II receptor blocker; CAD, coronary artery disease; HF, heart failure; ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist.